Keith Lenchner, MD
Allergy & Immunology · Atlanta, GANPI 1669421491
Payments from drug & device makers
Across 433 payments — averaging $25.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Pharming Healthcare, Inc.$966
- Sanofi$953
- GSK$684
- Takeda Pharmaceuticals U.S.A., Inc.$649
- Biocryst US Sales Co., LLC$575
- plus $4K from 30 others
What the payments were for
- Food & beverage$10,812100%
- Education$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 102 | $2,517 |
| Pharming Healthcare, Inc. | 33 | $966 |
| Sanofi | 35 | $953 |
| GSK | 37 | $684 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $649 |
| Biocryst US Sales Co., LLC | 23 | $575 |
| Regeneron Healthcare Solutions, Inc. | 21 | $570 |
| CSL Behring | 19 | $496 |
| Octapharma USA, Inc. | 9 | $440 |
| Novartis | 17 | $406 |
| Genentech USA, Inc. | 12 | $381 |
| Optinose US, Inc. | 13 | $260 |
| Grifols USA, LLC | 11 | $244 |
| Pfizer | 12 | $243 |
| Kaleo, Inc. | 12 | $232 |
| Amgen(2 entities) | 10 | $205 |
| Blueprint Medicines Corporation | 5 | $153 |
| Covis Pharma GmbH | 6 | $136 |
| Teva Pharmaceuticals USA, Inc. | 7 | $109 |
| LEO Pharma Inc. | 4 | $106 |
| Alk-abello, Inc | 3 | $64 |
| Jubilant Hollisterstier LLC | 1 | $57 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $45 |
| Lilly USA, LLC | 2 | $44 |
| Merck | 2 | $43 |
| Verona Pharma, Inc. | 1 | $34 |
| Tersera Therapeutics LLC | 1 | $28 |
| Ionis Pharmaceuticals, Inc. | 1 | $28 |
| Dermavant Sciences, Inc. | 1 | $26 |
| Mylan Specialty L.p. | 1 | $25 |
| Shire North American Group Inc | 1 | $23 |
| Cycle Pharmaceuticals Inc | 1 | $23 |
| Kedrion Biopharma, Inc. | 1 | $22 |
| AbbVie | 1 | $21 |
| Biocryst Pharmaceuticals, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,843 in reported general payments places this provider in the 65th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 42 | $132,793 |
| Dupixent SyringeDupilumab | 30 | $113,354 |
| TezspireTezepelumab-Ekko | 27 | $112,770 |
| HyqviaIgg/Hyaluronidase,recombinant | 12 | $68,111 |
| Breo ElliptaFluticasone/Vilanterol | 69 | $38,561 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $37,264 |
| Advair HfaFluticasone Propion/Salmeterol | 30 | $12,883 |
| Epinephrine | 70 | $10,891 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $10,739 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $7,123 |
| Wixela InhubFluticasone Propion/Salmeterol | 31 | $4,313 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 105 | $2,536 |
| Azelastine Hcl | 84 | $2,488 |
| Esomeprazole Magnesium | 33 | $1,694 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $1,684 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Symbicort | $2,517 | $119,89450 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $684 | $75,825121 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $649 | $68,11112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Atlanta
- Deborah BirxAtlanta$470K
- Paul RabinowitzAtlanta$94K
- Santhosh Kumar Bangalore Vasantha KumarAtlanta$60K
- Gerald LeeAtlanta$52K
- Luqman SeiduAtlanta$46K
- Alan ReddingAtlanta$23K
- David ReddingAtlanta$22K
- Merin KalangaraAtlanta$19K
- Glen NadelAtlanta$12K
- David TannerAtlanta$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.